By

phillipsandphillips
Close relatives of people with blood cancer are more likely to be diagnosed with the disease themselves, a major study has found. An international team, led out of the Institute of Cancer Research in London, examined diagnosis, birth and death records of more than 150,000 people with all types of blood cancer — such as leukaemia, lymphoma or myeloma...
Continue Reading
Highlights include: • Increased novel agent access in NZ improved MM survival • Pomalidomide-based regimens for relapsed/refractory MM • Daratumumab, lenalidomide + dexamethasone for untreated myeloma Download here: Multiple Myeloma Research Review Issue 31
Continue Reading
For those who are able to, including family and friends, we urge you to join us on Tuesday 7 May in Wellington to march for the RIGHT TO LIVE. We’ll be presenting our petition at the steps of Parliament to ask that the drugs that extend or improve the quality of lives are funded by...
Continue Reading
To date, the choice of therapy for an individual multiple myeloma patient has been based on clinical factors such as age and comorbidities. The widespread evolution, validation, and clinical utilization of molecular technologies, such as fluorescence in situ hybridization and next-generation sequencing has enabled the identification of a number of prognostic and predictive biomarkers for...
Continue Reading
Highlights include: Real-life safety and efficacy of autologous SCT in elderly MM Lenalidomide maintenance vs. observation for newly diagnosed MM Subclonal TP53 copy number is associated with MM prognosis Download here – Multiple Myeloma Research Review Issue 29
Continue Reading
Research Review Multiple Myeloma Summit Highlights include:  High risk MM outcomes 5-year results for CyBorD MRD for guiding myeloma treatment Burden of MM in NZ Download here
Continue Reading
Ken Romeril, CEO Myeloma New Zealand Charitable Trust invites you to the Myeloma New Zealand Christmas Function 12 December, 5.00pm at BNZ Partners Centre, Level 10 Ricoh House, 1 Victoria St Wellington RSVP by Friday 7 December to contact@multiplemyeloma.org.nz
Continue Reading
Issue 28 of Multiple Myeloma Research Review. Highlights include:  Elotuzumab monotherapy for smouldering MM Thereapetuc vulnerability of MM to Pri-17-92 inhibition Identification of novel mutational drivers reveals oncogene dependencies in MM Patient reported health-related Q0L from TOURMALINE-MM1 Download here
Continue Reading
INVITATION Patient Seminar: CAR T-Cell Therapy: a New Frontier in Blood Cancer Treatment Presented by Dr Rob Weinkove on 8 March, 5.30-7pm at Russell McVeagh, Level 24, Dimension Data House, 157 Lambton Quay RSVP by Friday 2 March to contact@multiplemyeloma.org.nz    
Continue Reading
1 2 3 4

Floor 7, 90 The Terrace
Wellington Central
New Zealand